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LETTERS TO THE EDITOR
Does the Addition of
Vascular Endothelial
Growth Factor
Inhibitors to Epidermal
Growth Factor
Receptor-Tyrosine
Kinase Inhibitor
Overcome T790M
Acquired Resistance?
To the Editor:
We previously reported the effi-
cacy of “high-dose erlotinib” (300 mg,
alternating days) for refractory brain
metastases in a patient with non-small
cell lung cancer.1 Six months after the
initiation of high-dose erlotinib, pro-
gressive disease was observed based on
an increase of left pleural effusion and
the progression of mediastinal lymph
nodes, although the brain metastases re-
mained stable (Figure 1A). Cytological
examination of the pleural effusion re-
vealed adenocarcinoma cells, and epi-
dermal growth factor receptor (EGFR)
gene mutational analysis detected a
T790M point mutation in exon 20 and a
G719S point mutation in exon 18. When
treatment with erlotinib was discontin-
ued, the brain metastases deteriorated
rapidly. So, we postulated that the brain
lesions depended on the sensitivity to
erlotinib and that erlotinib should not
have been discontinued. We decided to
add bevacizumab (15 mg/kg) every 3
weeks to the administration of high-dose
erlotinib. After the addition of bevaci-
zumab, the left pleural effusion was re-
duced without tube drainage, and the
patient’s respiratory symptoms (dyspnea
and productive cough) improved (Figure
1B). Although stable disease had been
maintained for 4 months, the patient’s
neurological symptoms (gait distur-
bance) deteriorated, indicating progres-
sion of the brain metastases, while stable
disease was maintained in the thoracic
lesions. The patient’s performance sta-
tus worsened, and the best supportive
care was chosen. Two weeks after the
discontinuation of erlotinib and bevaci-
zumab, the patient died.
The T790M secondary point muta-
tion in exon 20 has been demonstrated to
be a mechanism of acquired resistance to
EGFR-tyrosine kinase inhibitors (TKIs).2,3
Even if EGFR-TKIs show a good initial
response in patients with an activating
EGFR mutation, the progression-free sur-
vival is limited to approximately 1 year
because of the emergence of resistant
cells. Several agents or methods to over-
come this resistance mechanism are being
developed. Among them, irreversible
EGFR-TKIs are suggested to have the
potential to overcome T790M resistance.
On the other hand, recent reports have
suggested that dual inhibition of vascular
endothelial growth factor and EGFR may
be another strategy for overcoming
T790M resistance to EGFR-TKIs in
vivo.4,5 In fact, malignant pleural effusion
that contained T790M mutation-positive
cells was controlled for 4 months by the
combination therapy of bevacizumab and
erlotinib in our case. The addition of vas-
cular endothelial growth factor inhibitors
to EGFR-TKIs may be a treatment op-
tion for overcoming acquired T790Mmuta-
tion resistance to EGFR-TKIs. However,
this is only one case report, and future pro-
spective studies are warranted to validate
this combination strategy.
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FIGURE 1. A, Chest x-ray taken before the addition of bevacizumab to erlotinib.
B, Chest x-ray taken 2 months after the addition of bevacizumab to erlotinib.
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